Evaluation of weight-adjusted doses of palonosetron for prevention of postoperative nausea and vomiting in day care laparoscopic gynaecological surgery: A dose ranging, randomised controlled trial
BACKGROUNDPalonosetron 75 mcg is being used for the prevention of postoperative nausea and vomiting. However, weight-adjusted doses in laparoscopic surgery are unevaluated. AIMTo determine the response to three doses of palonosetron (0.5, 1.0, or 1.5 mcg kg) over 72 h in the postoperative period in women undergoing laparoscopic gynaecological procedures. DESIGNA randomised dose–response study. SETTINGA tertiary care hospital and research institute in north India from July to December 2014. PATIENTSAmerican society of Anesthesiologists physical status I and II women, from 18 to 60 years old, undergoing laparoscopic gynaecological procedures on a day care basis. METHODSPatients were randomised to receive palonosetron 0.5, 1 and 1.5 mcg kg intravenously before induction of anaesthesia. MAIN OUTCOMES MEASURESThe primary outcome was the proportion of patients with a complete response (i.e. who neither vomited nor required additional antiemetic drugs for nausea during the first 72 postoperative hours). The proportion of patients having nausea or emetic episodes and the requirement for rescue antiemetics and analgesics during the 72-h period were recorded as secondary outcomes. RESULTSWith palonosetron, there was a significant dose-dependent increase (37.5 vs. 67.5 vs. 75%, P < 0.001) in proportion of patients with a complete response during the 72 h. This was associated with a significant dose-dependent decrease in the proportion of patients with nausea (77.5 vs. 47.5 vs. 35%, P < 0.001) and vomiting (47.5 vs. 32.5 vs. 12.5%, P = 0.003). CONCLUSIONFollowing laparoscopic gynaecological surgery, intravenous palonosetron has a dose-dependent prophylactic effect against postoperative nausea and vomiting during the first 72 postoperative hours. TRIAL REGISTRATIONThe trial was registered with Clinical trial registry of India(CTRI/2014/09/004987)..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2016 |
---|---|
Erschienen: |
2016 |
Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
---|---|
Enthalten in: |
European journal of anaesthesiology - 33(2016), 2, Seite 104-109 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jain, Divya [VerfasserIn] |
---|
Links: |
---|
doi: |
10.1097/EJA.0000000000000391 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC1972024205 |
---|
LEADER | 01000caa a2200265 4500 | ||
---|---|---|---|
001 | OLC1972024205 | ||
003 | DE-627 | ||
005 | 20230509191629.0 | ||
007 | tu | ||
008 | 160308s2016 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1097/EJA.0000000000000391 |2 doi | |
028 | 5 | 2 | |a PQ20160307 |
035 | |a (DE-627)OLC1972024205 | ||
035 | |a (DE-599)GBVOLC1972024205 | ||
035 | |a (PRQ)p687-218602ba18dcdbfda0e12e38961e88222d9210b1bcb291b10ba0fa591974dbc00 | ||
035 | |a (KEY)0133805620160000033000200104evaluationofweightadjusteddosesofpalonosetronforpr | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q DNB |
100 | 1 | |a Jain, Divya |e verfasserin |4 aut | |
245 | 1 | 0 | |a Evaluation of weight-adjusted doses of palonosetron for prevention of postoperative nausea and vomiting in day care laparoscopic gynaecological surgery: A dose ranging, randomised controlled trial |
264 | 1 | |c 2016 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
520 | |a BACKGROUNDPalonosetron 75 mcg is being used for the prevention of postoperative nausea and vomiting. However, weight-adjusted doses in laparoscopic surgery are unevaluated. AIMTo determine the response to three doses of palonosetron (0.5, 1.0, or 1.5 mcg kg) over 72 h in the postoperative period in women undergoing laparoscopic gynaecological procedures. DESIGNA randomised dose–response study. SETTINGA tertiary care hospital and research institute in north India from July to December 2014. PATIENTSAmerican society of Anesthesiologists physical status I and II women, from 18 to 60 years old, undergoing laparoscopic gynaecological procedures on a day care basis. METHODSPatients were randomised to receive palonosetron 0.5, 1 and 1.5 mcg kg intravenously before induction of anaesthesia. MAIN OUTCOMES MEASURESThe primary outcome was the proportion of patients with a complete response (i.e. who neither vomited nor required additional antiemetic drugs for nausea during the first 72 postoperative hours). The proportion of patients having nausea or emetic episodes and the requirement for rescue antiemetics and analgesics during the 72-h period were recorded as secondary outcomes. RESULTSWith palonosetron, there was a significant dose-dependent increase (37.5 vs. 67.5 vs. 75%, P < 0.001) in proportion of patients with a complete response during the 72 h. This was associated with a significant dose-dependent decrease in the proportion of patients with nausea (77.5 vs. 47.5 vs. 35%, P < 0.001) and vomiting (47.5 vs. 32.5 vs. 12.5%, P = 0.003). CONCLUSIONFollowing laparoscopic gynaecological surgery, intravenous palonosetron has a dose-dependent prophylactic effect against postoperative nausea and vomiting during the first 72 postoperative hours. TRIAL REGISTRATIONThe trial was registered with Clinical trial registry of India(CTRI/2014/09/004987). | ||
540 | |a Nutzungsrecht: © 2016 European Society of Anaesthesiology | ||
700 | 1 | |a Bala, Indu |4 oth | |
700 | 1 | |a Jain, Kajal |4 oth | |
700 | 1 | |a Gandhi, Komal |4 oth | |
773 | 0 | 8 | |i Enthalten in |t European journal of anaesthesiology |d Philadelphia, Pa. : Lippincott Williams & Wilkins, 1984 |g 33(2016), 2, Seite 104-109 |w (DE-627)167919792 |w (DE-600)605770-6 |w (DE-576)015905225 |x 0265-0215 |7 nnns |
773 | 1 | 8 | |g volume:33 |g year:2016 |g number:2 |g pages:104-109 |
856 | 4 | 1 | |u http://dx.doi.org/10.1097/EJA.0000000000000391 |3 Volltext |
856 | 4 | 2 | |u http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00003643-201602000-00007 |
856 | 4 | 2 | |u http://www.ncbi.nlm.nih.gov/pubmed/26673802 |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OLC-DE-84 | ||
912 | |a GBV_ILN_2002 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4219 | ||
912 | |a GBV_ILN_4306 | ||
951 | |a AR | ||
952 | |d 33 |j 2016 |e 2 |h 104-109 |